MiNK Therapeutics(INKT)
$8.02-0.59 (-6.85%)
INKT
MiNK Therapeutics stock drug pipeline
$8.02
At close:-0.59 (-6.85%)
Want to see INKT full AI Analyst Report?
MiNK Therapeutics (INKT) Drug Pipeline
275 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Standard Of Care, Agent-797 | Pneumonia | Phase II | Recruiting | A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure | May 22, 2026 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Standard Of Care, Agent-797 | Phase II | Pneumonia | Recruiting | A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure | May 22, 2026 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mink Therapeutics, Inc. (INKT) have in its pipeline
MiNK Therapeutics INKT is currently developing the following drugs: Standard Of Care, Agent-797. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

